Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Decreases By 75.2%

Pulmatrix, Inc. (NASDAQ:PULM) saw a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 4,171 shares, a drop of 75.2% from the July 30th total of 16,792 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 8,523 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Pulmatrix Stock Down 0.7%

Shares of PULM traded down $0.01 during trading hours on Friday, reaching $1.51. 3,317 shares of the company traded hands, compared to its average volume of 41,137. The company’s fifty day moving average price is $1.64 and its two-hundred day moving average price is $1.69. The company has a market capitalization of $5.51 million, a price-to-earnings ratio of -1.37 and a beta of 1.91. Pulmatrix has a 12 month low of $1.16 and a 12 month high of $5.50.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.00) by $1.71.

Institutional Investors Weigh In On Pulmatrix

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Pulmatrix during the second quarter valued at $93,000. DRW Securities LLC bought a new position in shares of Pulmatrix in the 4th quarter worth about $46,000. Finally, Dimensional Fund Advisors LP purchased a new position in Pulmatrix during the 3rd quarter valued at about $52,000. 11.84% of the stock is owned by hedge funds and other institutional investors.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).